Skip to main content

Table 5 Most frequently (occurring in >1 patient) reported serious adverse events

From: An open-label, sequential, dose-finding study of peginesatide for the maintenance treatment of anemia in chronic hemodialysis patients

Serious Adverse Event, no. (%)

Total n = 164

Congestive cardiac failure

6 (3.7)

Pneumonia

4 (2.4)

Acute myocardial infarction

3 (1.8)

Convulsion

3 (1.8)

Pulmonary edema

3 (1.8)

Sepsis

3 (1.8)

Catheter sepsis

2 (1.2)

Coronary artery disease

2 (1.2)

Hypotension

2 (1.2)

Pneumonia, aspiration

2 (1.2)

Pulmonary embolism

2 (1.2)

Respiratory failure

2 (1.2)